The largest systematic review to date (Bylsma et al., 2023) reported DLL3 positivity in 80–93.5% of SCLC tumors using a threshold of ≥1% tumor cells and 58.3–91.1% with ≥25% expression. Here, DLL3 is linked to neoplasm.